D
Dierk Samel
Researcher at University of Stuttgart
Publications - 4
Citations - 705
Dierk Samel is an academic researcher from University of Stuttgart. The author has contributed to research in topics: Apoptosis & TRAF2. The author has an hindex of 4, co-authored 4 publications receiving 670 citations.
Papers
More filters
Journal ArticleDOI
Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8
Mariola Fotin-Mleczek,Frank Henkler,Dierk Samel,Monica Reichwein,Angelika Hausser,Ingela Parmryd,Peter Scheurich,Johannes A. Schmid,Harald Wajant +8 more
TL;DR: T NF-R2 triggering can interfere with TNF-R1-induced apoptosis by inhibition of NF-kappaB-dependent production ofAnti-apoptotic factors and by blocking the action of anti-ap optotic factors at the post-transcriptional level.
Journal ArticleDOI
NFκB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP
Sebastian Kreuz,Daniela Siegmund,Jost-Julian Rumpf,Dierk Samel,Martin Leverkus,Ottmar Janssen,Georg Häcker,Oliver Dittrich-Breiholz,Michael Kracht,Peter Scheurich,Harald Wajant +10 more
TL;DR: Protection against Fas-induced apoptosis in a FLIP-independent manner converted a proapoptotic Fas signal into an inflammatory NFκB-related response.
Journal ArticleDOI
Tumor Necrosis Factor Receptor-associated Factor (TRAF) 1 Regulates CD40-induced TRAF2-mediated NF-κB Activation
Mariola Fotin-Mleczek,Frank Henkler,Angelika Hausser,Heike Glauner,Dierk Samel,Angela Graness,Peter Scheurich,Davide Mauri,Harald Wajant +8 more
TL;DR: It is proposed that the stoichiometry of TRAF1-TRAF2 heteromeric complexes determines their capability to mediate CD40 signaling but has no major effect on TNF signaling.
Journal ArticleDOI
Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted Activation.
Dierk Samel,Dafne Müller,Jeannette Gerspach,Constance Assohou-Luty,Gabriele Sass,Gisa Tiegs,Klaus Pfizenmaier,Harald Wajant +7 more
TL;DR: The principle described here for the first time, in which cell-surface antigen-mediatedactivation of Fas permits local activation of Fas in vivo, opens novel avenues for the use of Fas signaling in cancer therapy.